Martina Garau : Citation Profile


Are you Martina Garau?

Office of Health Economics

4

H index

2

i10 index

52

Citations

RESEARCH PRODUCTION:

1

Articles

25

Papers

1

Books

RESEARCH ACTIVITY:

   14 years (2006 - 2020). See details.
   Cites by year: 3
   Journals where Martina Garau has often published
   Relations with other researchers
   Recent citing documents: 10.    Total self citations: 6 (10.34 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pga966
   Updated: 2022-09-24    RAS profile: 2020-07-23    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Towse, Adrian (2)

Sampson, Christopher (2)

Zamora Talaya, Bernarda (2)

Neri, Margherita (2)

Zhang, Kyann (2)

Authors registered in RePEc who have co-authored more than one work in the last five years with Martina Garau.

Is cited by:

Towse, Adrian (4)

Shah, Koonal (4)

Devlin, Nancy (1)

Sanchez Martinez, Fernando Ignacio (1)

Hampson, Grace (1)

Scuffham, Paul (1)

Mott, David (1)

LEVAGGI, ROSELLA (1)

Grassano, Nicola (1)

Hollis, Aidan (1)

Berdud, Mikel (1)

Cites to:

Towse, Adrian (8)

Devlin, Nancy (7)

Danzon, Patricia (4)

Brazier, John (3)

Andreoni, James (3)

Rice, Nigel (3)

Parkin, David (3)

Shah, Koonal (3)

Tsuchiya, Aki (3)

Docteur, Elizabeth (3)

Claxton, Karl (2)

Main data


Where Martina Garau has published?


Working Papers Series with more than one paper published# docs
Consulting Reports / Office of Health Economics13
Research Papers / Office of Health Economics7
Briefings / Office of Health Economics4

Recent works citing Martina Garau (2022 and 2021)


YearTitle of citing document
2021Overcoming inefficiencies in the development of personalized medicine. (2021). Wuttke, David A ; Heese, Sebastian H ; Lutkemeyer, Daniel. In: European Journal of Operational Research. RePEc:eee:ejores:v:290:y:2021:i:1:p:278-296.

Full description at Econpapers || Download paper

2021.

Full description at Econpapers || Download paper

2021Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?. (2021). Cubi-Molla, Patricia ; Devlin, Nancy ; Buxton, Martin. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:19:y:2021:i:5:d:10.1007_s40258-021-00648-2.

Full description at Econpapers || Download paper

2022Consideration of quality of life in the health technology assessments of rare disease treatments. (2022). Drummond, Michael ; Facey, Karen ; Upadhyaya, Sheela ; Whittal, Amanda ; Meregaglia, Michela ; Nicod, Elena. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:23:y:2022:i:4:d:10.1007_s10198-021-01387-w.

Full description at Econpapers || Download paper

2021The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment. (2021). Meregaglia, Michela ; Whittal, Amanda ; Nicod, Elena. In: The Patient: Patient-Centered Outcomes Research. RePEc:spr:patien:v:14:y:2021:i:5:d:10.1007_s40271-020-00493-w.

Full description at Econpapers || Download paper

2021Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis. (2021). Kim, Hansoo ; Liew, Danny ; Goodall, Stephen ; Cook, Greg . In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:5:y:2021:i:3:d:10.1007_s41669-021-00265-8.

Full description at Econpapers || Download paper

2021Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Per. (2021). Steier, Joerg S ; Blissett, Deirdre B ; Karagama, Yakubu G. In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:5:y:2021:i:3:d:10.1007_s41669-021-00266-7.

Full description at Econpapers || Download paper

2021Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review. (2021). Campbell, Jonathan D ; Nemeth, Bertalan ; Elezbawy, Baher ; Mendola, Nicholas D ; Zelei, Tamas. In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:5:y:2021:i:4:d:10.1007_s41669-021-00271-w.

Full description at Econpapers || Download paper

2022Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden. (2022). Heeg, B ; Ostby, Torup J ; Jakobsson, M ; Russell-Smith, T A ; Oostrum, I. In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:6:y:2022:i:1:d:10.1007_s41669-021-00287-2.

Full description at Econpapers || Download paper

2021The economic theory of cost?effectiveness thresholds in health: Domestic and international implications. (2021). Hollis, Aidan ; Moradpour, Javad. In: Health Economics. RePEc:wly:hlthec:v:30:y:2021:i:5:p:1139-1151.

Full description at Econpapers || Download paper

Works by Martina Garau:


YearTitleTypeCited
2009Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries In: Briefings.
[Full Text][Citation analysis]
paper6
2007Estimating Pharmaceutical Companies Value to the Nation: Case Study of the British Pharma Group In: Briefings.
[Full Text][Citation analysis]
paper0
2018Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward In: Briefings.
[Full Text][Citation analysis]
paper2
2019How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy In: Briefings.
[Full Text][Citation analysis]
paper1
2011Exploring the Interdependency between Public and Charitable Medical Research In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2010Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2009Assessment and Appraisal of Oncology Medicines: NICEs Approach and International HTA Experience In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2006Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2014Obstructive Sleep Apnoea: Health Economics Report In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2016Improving Efficiency and Resource Allocation in Future Cancer Care In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2017Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2017Policy Options for Formulary Development in Middle-income Countries In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2017Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2018Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2019Unrelieved Pain in Palliative Care in England In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2020Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making? In: Consulting Reports.
[Full Text][Citation analysis]
paper2
2020International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2007European Medicines Pricing and Reimbursement: Now and the Future In: Monographs.
[Full Text][Citation analysis]
book0
2011Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? In: Occasional Papers.
[Full Text][Citation analysis]
paper2
2013Exploring the link between health and wealth in decision making In: Research Papers.
[Full Text][Citation analysis]
paper0
2013Multi-Criteria Decision Analysis to Value Orphan Medicines In: Research Papers.
[Full Text][Citation analysis]
paper14
2012Can and Should Value Based Pricing Be Applied to Molecular Diagnostics? In: Research Papers.
[Full Text][Citation analysis]
paper5
2010Using QALYs in Cancer: Review of the Methodological Limitations In: Research Papers.
[Full Text][Citation analysis]
paper12
2014Exploring the Interdependencies of Research Funders in the UK In: Research Papers.
[Full Text][Citation analysis]
paper2
2016Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) In: Research Papers.
[Full Text][Citation analysis]
paper0
2018Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).(2018) In: PharmacoEconomics - Open.
[Full Text][Citation analysis]
This paper has another version. Agregated cites: 0
article
2018R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C In: Research Papers.
[Full Text][Citation analysis]
paper2

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated August, 1st 2022. Contact: CitEc Team